Product Information
IBANDRONATE 3 MG/3 ML SYRINGE is a generic product labeled by Mylan Institutional LLC, priced at $54.2117 per ML under NDC 67457052433. Its NADAC has been published 80 times since Nov 20, 2024.
FDA first approved this application on Sep 2, 2014.
Strength
3 mg/3mL
Manufacturer
Mylan Institutional LLCNDC
67457052433
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
INTRAVENOUS
Effective Date
3/18/2026
Active Ingredients
IBANDRONATE SODIUMApproval Type
Generic (ANDA)
FDA Application
ANDA202671FDA Approved
9/2/2014
On Market Since
9/2/2014
Pharmacological Classes
Price Statistics
The NADAC for IBANDRONATE 3 MG/3 ML SYRINGE has been published 80 times since Nov 20, 2024, and over the history we have for it it has risen 3.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $54.2117 per ML |
|---|---|
| All-time high | $54.2117 (May 27, 2026) |
| All-time low | $49.5953 (Oct 22, 2025) |
| 52-week high | $54.2117 |
| 52-week low | $49.5953 |
| Median price | $53.3244 |
| Average price | $52.9088 |
| Largest weekly change | -7.0% (Oct 22, 2025) |
| Weeks tracked | 80 |
| Tracking since | Nov 20, 2024 |
1W
N/A
1M
N/A
3M
N/A
6M
0.0%
1Y
+1.7%
3Y
N/A
5Y
N/A
All
+3.4%
Last surveyed May 27, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 3% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Institutional LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ibandronate sodium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Bisphosphonate class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of IBANDRONATE 3 MG/3 ML SYRINGE?
The current National Average Drug Acquisition Cost (NADAC) for IBANDRONATE 3 MG/3 ML SYRINGE, manufactured by Mylan Institutional LLC, is $54.2117 per ML (NDC 67457052433), effective May 27, 2026.
How has the price of IBANDRONATE 3 MG/3 ML SYRINGE changed over time?
Over the history we have for it, the NADAC for IBANDRONATE 3 MG/3 ML SYRINGE has risen 3.4%. It has been tracked across 80 weekly CMS publications since Nov 20, 2024.
What are the highest and lowest recorded NADAC prices for IBANDRONATE 3 MG/3 ML SYRINGE?
Since Nov 20, 2024, the NADAC for IBANDRONATE 3 MG/3 ML SYRINGE has ranged from a low of $49.5953 (Oct 22, 2025) to a high of $54.2117 (May 27, 2026), with a median of $53.3244 per ML.
Are there cheaper alternatives to IBANDRONATE 3 MG/3 ML SYRINGE?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, IBANDRONATE 3 MG/3 ML SYRINGE, is $52.6478 per ML — about 3% below IBANDRONATE 3 MG/3 ML SYRINGE.
Who manufactures IBANDRONATE 3 MG/3 ML SYRINGE?
IBANDRONATE 3 MG/3 ML SYRINGE (NDC 67457052433) is labeled by Mylan Institutional LLC, and CMS classifies it as a generic product.